NR4A1 and breast cancer: Women with hormone receptor HR-positive (HR +) BC that is confined to the breast and ipsilateral axillary lymph nodes generally have a favorable short-term prognosis with five-year relative survival rates of 98%, 94%, and 82% for American Joint Committee on Cancer (AJCC) stages I, II, and III disease, respectively [2].